Mainz Biomed N.V., a molecular genetics diagnostic company focused on early cancer detection, announced the pricing of a $3.0 million follow-on offering. The offering includes 2,222,222 units, each comprising one ordinary share (or a pre-funded warrant as an alternative) and one Series A warrant to purchase one and a half ordinary shares. The units are priced at $1.35 each, with the Series A warrants exercisable at the same price, expiring five years from issuance. This offering is conducted under an SEC-approved registration statement, with Maxim Group LLC as the sole placement agent. The transaction is expected to close around August 5, 2025, subject to customary closing conditions.